Routine employment agreement formalization for existing top executives — no trading signal. Monitor future 8-Ks for any changes to the Gyre Therapeutics 2023 Omnibus Incentive Plan or equity grant activity that could signal dilution.
Price Chart
Executive Summary
Gyre Therapeutics entered into formal employment agreements with CEO Ying Luo and CFO Thomas Eastling on October 16, 2026, formalizing their at-will employment, base salaries, and severance terms. The agreements are routine compensatory arrangements for existing officers and contain no material financial surprises or changes to the company's strategic direction.
Key Facts
- CEO Ying Luo receives annual base salary of $500,000 and 2026 target bonus of $150,000
- CFO Thomas Eastling receives annual base salary of $339,066 and 2026 target bonus of $70,000
- Both agreements are at-will with standard severance: 6 months base salary (non-CIC) or lump sum of base + target bonus (CIC), plus 12 months COBRA and partial/full equity acceleration
- Agreements dated October 16, 2026; filed as 8-K on October 22, 2026
- No departures, resignations, or unexpected changes — both officers continue in their existing roles
Financial Impact
CEO total annual cash compensation of $650,000 ($500k base + $150k target bonus); CFO total annual cash compensation of $409,066 ($339,066 base + $70k target bonus). No impact on company financials.
Risk Factors
- No material risks identified from this filing alone
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-040506 |
| Document: ef20080299_ex10-2.htm | 0001140361-26-040506 |
| Document: ef20080299_8k.htm | 0001140361-26-040506 |
| Document: 0001140361-26-040506-index-headers.html | 0001140361-26-040506 |
| Document: 0001140361-26-040506-index.html | 0001140361-26-040506 |
| Document: 0001140361-26-040506.txt | 0001140361-26-040506 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $5.85 | awaiting T+20 | — | $6.43 (+9.91%) |
Sep 1, 2026 8w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $6.43 (−0.62%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $6.43 (−3.31%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $6.43 (+3.60%) |
Aug 4, 2026 12w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $6.43 (+4.55%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $6.43 (+1.42%) |
Jun 2, 2026 21w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $6.43 (+15.65%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $6.43 (−1.83%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.43 (−18.81%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.43 (−18.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers